Asia Deal Watch: Takeda Licenses Curadev STING Agonist To Further Its IO Ambitions

 
• By Ian Haydock, Brian Yang, Anju Ghangurde, Jung Won Shin, and Joseph Haas

The Japanese pharma, continuing to bolster its pipeline after buying Shire, is partnering with Skyhawk in neurodegenerative diseases under another new deal. Also, Purdue cites shifting business priorities for a decision to end Eisai collaboration on sleep disorder drug.

asian man in bed suffering insomnia and sleep disorder thinking about his problem at night - Image
Eisai now owns all rights to insomnia candidate lemborexant

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Strategic Transactions.

Takeda Pharmaceutical Co. Ltd

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business